Wockhardt Limited submitted a press release regarding the successful use of Zaynich™ in a US cancer patient, enabling her to undergo a liver transplant after eradicating drug-resistant infections. The treatment was necessary after the patient failed to respond to other antibiotics, highlighting the effectiveness of Zidebactam/Cefepime in critical cases.
Wockhardt Limited has informed the Exchange regarding a press release dated December 16, 2024, titled "Zaynich (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens".